SNDX-5613
2021-1059
Phase 2 small_molecule active
Quick answer
SNDX-5613 for Acute Myeloid Leukemia is a Phase 2 program (small_molecule) at Syndax Pharmaceuticals Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Syndax Pharmaceuticals Inc
- Indication
- Acute Myeloid Leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active